Factors associated with long term Rituximab use in Rheumatoid Arthritis – Results from the British Society of Rheumatology Biologics Register
Alexander Oldroyd(Manchester Academic Health Science Centre), Kimme L Hyrich(Manchester Royal Infirmary), Deborah Symmons(University of Manchester), Jamie C. Sergeant(Manchester Academic Health Science Centre), Mark Lunt(University of Cambridge), Lianne Kearsley‐Fleet(University of Manchester), Kath Watson(University of Manchester)
Research Explorer (The University of Manchester)
January 1, 2015
Cited by 0
Related Papers
Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
|BMJ|2020|3.3k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
|Annals of the Rheumatic Diseases|2009|708
High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis
|Nature Genetics|2012|677
EULAR definition of difficult-to-treat rheumatoid arthritis
|Annals of the Rheumatic Diseases|2020|538